Recombinant HCMV and RHCMV vectors and uses thereof
US9982241B2 · kind B2 · utility
13Cited by
10References
54Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 1, 2015 |
| Grant date | May 29, 2018 |
| Priority date | — |
| Expiry date | Oct 1, 2035 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The recombinant rhesus cytomegalovirus (RhCMV) and human cytomegalovirus (HCMV) vectors of this invention encode heterologous antigens, such as pathogen-specific antigens or tumor antigens, which may be used, for example, for the treatment or prevention of infectious disease or cancer. The recombinant RhCMV or HCMV vectors elicit and maintain high level cellular immune responses specific for the heterologous antigen while including deletions in one or more genes essential or augmenting for CMV replication, dissemination or spread.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.